INVA Innoviva, Inc.

OBB
$21.19

Innoviva, Inc. (INVA) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is $0.50 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.3% since its last earnings release on August 5, 2026.

Innoviva Beat Consensus Estimates
Wednesday, August 5, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs $0.50
Rev est $113.04M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $20.82

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Innoviva, Inc.

Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.

Sector

Healthcare

Industry

Drug Manufacturers / Major